These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33717226)

  • 1. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors.
    Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
    Ther Adv Med Oncol; 2021; 13():1758835921992992. PubMed ID: 33717226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
    Kim H; Ahn S; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2427-2435. PubMed ID: 34510272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
    Kim H; Kim H; Kim R; Jo H; Kim HR; Hong J; Park JO; Park YS; Kim ST
    Technol Cancer Res Treat; 2021; 20():15330338211062324. PubMed ID: 34855561
    [No Abstract]   [Full Text] [Related]  

  • 4. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical utility of tumor mutational burden in non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
    Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
    Front Oncol; 2020; 10():314. PubMed ID: 32232003
    [No Abstract]   [Full Text] [Related]  

  • 9. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
    Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
    Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
    Jung J; Heo YJ; Park S
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
    Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
    Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
    Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
    Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
    Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N
    Front Immunol; 2021; 12():631483. PubMed ID: 33732253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
    Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
    Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
    Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.